Publications by authors named "G L Colice"
Article Synopsis
- * A study analyzed its effectiveness at a fixed dose of 210 mg every 4 weeks, using data from over 1300 asthma patients and healthy participants across multiple clinical trials.
- * The results showed a stable pharmacokinetic profile with no significant influence from various patient factors, confirming that the fixed-dose regimen is suitable for treating eligible patients with severe asthma.
Article Synopsis
- Mucus plugs in asthmatic patients are linked to airway obstruction and inflammatory cytokines (IL-5 and IL-13), making them a target for specific treatments like tezepelumab.
- The CASCADE trial utilized CT imaging to evaluate the effect of tezepelumab on mucus plugs in individuals with uncontrolled asthma through a placebo-controlled setup involving 37 patients treated with the drug and 45 with a placebo.
- Results showed that those receiving tezepelumab had a significant decrease in mucus plug scores, which correlated with improved lung function and lower levels of inflammatory biomarkers, compared to placebo recipients.
Introduction: Annual influenza vaccinations are recommended for adolescents and adults with moderate to severe asthma. This study investigated the effect of tezepelumab, a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin, on the humoral immune response to the quadrivalent seasonal influenza vaccine in patients with moderate to severe asthma.
Methods: VECTOR was a phase 3b, randomized, multicenter, double-blind, parallel-group, placebo-controlled study.
What Is This Summary About?: This is a summary of the results of 2 clinical studies that looked at a medicine called Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the treatment of severe, uncontrolled asthma in people aged 12 and above. The results of these 2 studies, called and , formed the basis for tezepelumab's approval for use. Tezepelumab is a type of biologic treatment called an antibody.
View Article and Find Full Text PDFArticle Synopsis
- Tezepelumab significantly improved lung function in patients with severe, uncontrolled asthma over 52 weeks, showing better results compared to placebo in several key measurements, including pre-bronchodilator FEV and post-bronchodilator FEV.
- The NAVIGATOR study, which involved a double-blind, placebo-controlled design, treated patients aged 12-80 who were already on high-dose inhaled corticosteroids and other medications, with a randomized allocation to either tezepelumab or placebo.
- Results indicated that improvements in lung function were seen early and maintained throughout the study, especially in patients with shorter disease duration and specific baseline lung function conditions.